Krystal Biotech, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:KRYS
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 624 out of 928
Universe
Global Universe 12681 out of 16421
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd. |
22.1
Medium
|
121 out of 928 |
| Livzon Pharmaceutical Group, Inc. |
25.2
Medium
|
218 out of 928 |
| Shenyang Xingqi Pharmaceutical Co., Ltd. |
31.9
High
|
613 out of 928 |
| Krystal Biotech, Inc. |
32.1
High
|
624 out of 928 |
| Shijiazhuang Yiling Pharmaceutical Co., Ltd. |
35.6
High
|
787 out of 928 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.